BioWorld A closer look BioWorld Asia BioWorld Science

BioWorld

Immunovant rises on IMVT-1402 data in difficult-to-treat RA
Shares of Immunovant Inc. (NASDAQ:IMVT) gained 35% after the firm disclosed early but “compelling” data from a phase IIb study testing next-generation FcRn inhibitor...

More in BioWorld

BioWorld Science

Unmasking the X: EPAC2 shifts the fragile X landscape
Researchers at UCLA have shown that divergent neuronal signaling in fragile X mice converges on EPAC2, a druggable target whose inhibition restores circuit activity and...

More in BioWorld Science

A closer look

Tracking hantavirus across the globe
The recent hantavirus outbreak aboard the MV Hondius cruise ship has brought increased attention to an infection for which there are no widely available or FDA-approved...

More in A closer look

BioWorld Asia

Fosun secures rights to Aribio’s AR-1001 in potential $4.7B deal
Shanghai Fosun Pharmaceutical (Group) Co. Ltd. is paying $60 million up front for an option to secure exclusive rights to Aribio Co. Ltd.’s oral phase III-stage Alzheimer’s...

More in BioWorld Asia

BioWorld Insider podcast

The opioid crisis may not be front and center anymore, but it’s raging still. Elysium Therapeutics Inc. CEO Greg Sturmer talks about his firm’s candidate for a solution to the medical and societal problem.